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Summary A major problem associated with the chemosensitivity testing of fresh human tumour cells using
the MTT assay is the contamination of nonmalignant cells in the tumour tissues. Highly purified fresh human
gastric cancer cells could be obtained from 43 solid tumours and eight malignant ascites for the MTT assay.
The success rate of the MTT assay was 87.9% (51 of the 58 cases), and the purity of tumour cells was greater
than 90% after separation on Ficoll-Hypaque and Percoll discontinuous gradients in primary, or metastatic
lesions, and also ascites. Cisplatin, mitomycin, and doxorubicin were more potent drugs than etoposide and
5-FU against gastric cancer cells. The chemosensitivity in differentiated cancer was equivalent to that in
non-differentiated cancer. Twenty of the 51 patients with gastric cancer had evaluable lesions, and they
received chemotherapy according to the results of the MTT assay using highly purified tumour cells. A clinical
response was obtained in 12 of these 20 patients (response rate: 60.0%; five with complete response, seven with
partial response).
A rapid colorimetric assay was described by Mosmann (1983)
for determining the ability of viable cells to convert a soluble
tetrazolium salt, 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT), into an insoluble formazan pre-
cipitate. The MTT assay is a rapid and quantitative colori-
metric system for the determination of the chemosensitivity
of tumour cell lines (Carmichael et al., 1987; Park et al.,
1987; Schroyens et al., 1990), and also in fresh leukaemia
cells (Twentyman et al., 1989; Pieters et al., 1989; Hanson et
al., 1991). However, the use of this assay for solid tumour
tissues has been limited because of contamination by non-
malignant cells in tumour specimens (Kaspers et al., 1991;
Campling et al., 1991; Suto, 1991). Thus, when the MTT
assay is employed for chemosensitivity testing of tumour
samples, highly purified fresh tumour cells should be used,
because contamination by nonmalignant cells affects the
results of this assay (Yamaue et al., 1991; Campling et al.,
1991; Suto, 1991).
The present study was designed to determine the chemo-
sensitivity in fresh human gastric cancer, using highly puri-
fied tumour cells, and the correlation of this sensitivity with
clinical response.
Patients and methods
Fifty-eight patients with gastric cancer were entered in this
study. Tumour specimens and ascites were taken for diagnos-
tic or therapeutic indications, and the informed consent of
the patients was obtained for the use of samples for drug
sensitivity testing. The MTT assay could be performed in 51
of the 58 patients (success rate: 87.9%). The reasons for the
seven unsuccessful assays were: four with low optical density
(OD57); less than 0.1 after culture, two with few viable cells
due to tumour necrosis, and one with bacterial contamina-
tion during culture. Surgical specimens were obtained from
43 of the 51 patients; 33 patients had primary gastric lesions,
eight had metastatic lymph nodes, one had liver metastasis,
and one had ovary metastasis. Peritoneal effusions were col-
lected for analysis from eight patients with disseminated
gastric cancer. The clinical stages of the 51 patients according
to the TNM classification of malignant tumours by UICC
were: four with Stage II, 12 with Stage IIIB, and 35 with
Stage IV.
None of these patients had received any previous anti-
tumour drugs.
Antitumour drugs
The antitumour drugs tested were cisplatin (CDDP), etopo-
side (VP-16), mitomycin C (MMC), doxorubicin (DOX), and
5-fluorouracil (5-FU). Each drug was diluted in complete
medium at therapeutic peak plasma concentration (Cmax x 1)
achieved by intravenous administration of clinical doses
(Scheithauer et al., 1986). The values were: MMC 1.0 jg
ml-'; 5-FU IOLgml-'; DOX 0.4figml-'; CDDP 2.0 Lg
ml-'; and VP-16 10tggml
, and 10-fold equivalents were
also prepared (Cmax x 10). The complete medium used con-
sisted of RPMI-1640 (Nissui Co., Tokyo, Japan) supple-
mented with 10% heat-inactivated foetal calf serum (GIBCO,
New York, USA), 2 mM L-glutamine, and antibiotics
(100 U penicillin ml' and 100 fig streptomycinml-').
Purification offresh human gastric cancer cells
Malignant ascites was immediately centrifuged at 400 g for
5 min and then suspended in complete medium. Freshly
excised tumour tissues were processed using enzymatic diges-
tion, as previously described (Yamaue et al., 1990a). Briefly,
tumour tissues were dissected into pieces smaller than 2 mm3
which were immersed in complete medium containing colla-
genase (2 mgml-', type V-S; Sigma), hyaluronidase (10 units
ml-,, type IV-S; Sigma), and DNase-I (0.4 mg ml-'; Sigma).
After 40 min incubation at 37°C, the cells were harvested,
washed, and suspended in complete medium.
The purification of autologous tumour cells has also been
previously described (Yamaue et al., 1990b; 1991). Tumour
cells obtained from solid tumour specimens and ascites were
centrifuged on Ficoll-Hypaque (specific gravity 1.077; Phar-
macia, Uppsala, Sweden) gradients at 400 g for 30min in
50 ml tubes. The interface was collected, and suspended at a
concentration of x 106ml-' in complete medium. The cells
were then layered on discontinuous gradients consisting of
10 ml of 100% and 15 ml of 75% Ficoll-Hypaque in 50 ml
plastic tubes. After centrifugation at 400 g for 30 min, a
tumour cell-rich fraction was collected from the 75% inter-
face. The tumour cell-enriched suspension was then layered
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onto discontinuous gradients containing 4 ml each of 25%,
15%, and 10% Percoll (Pharmacia, Uppsala, Sweden) in
complete medium in 15 ml plastic tubes. Centrifugation was
performed at 25 g for 7 min, and tumour cells depleted of
lymphoid cells were collected from the bottom and from the
25% interface, and suspended in complete medium at a
concentration of 1 x 106ml- . The cells thus prepared were
primarily tumour cells, with less than 10% contamination by
nonmalignant cells, as judged by morphologic examination
using Papanicolaou staining or carcinoembryonic antigen
(CEA) staining for CEA-positive tumour cells. The cells were
found to be more than 90-95% viable by the trypan blue
dye exclusion test. The nonmalignant cells including tumour-
infiltrating lymphocytes, fibroblasts, and mesothelial cells,
were removed by the purification procedures. The mean yield
of purified tumour cells was 2.5 ± 0.7 x 106, and the tumour
cell count at the beginning of preparation was 14 ± 4.3 x 106
(rate of yield: 17.9%)
Method ofMTT assay
Chemosensitivity was assessed using the tetrazolium salt
MTT (Sigma No. M2128) to measure the viability of tumour
cells (Mosmann, 1983; Yamaue et al., 1991). One hundred
of tumour cells suspension (1 x 106 cells ml-1) was added to
25pl of each drug at final concentration of Cmax x 10 and
Cmax x 1, in 96-well flat-bottomed microtitre plates (Corn-
ing No. 25860), and incubated at 37°C in a humidified 5%
CO2 atmosphere for 96 h. The chemosensitivity assay was
assessed in triplicate. Three microtitre wells containing
tumour cells suspended in 125 "l of complete medium (total
tumour cell number was equivalent to that in the test wells)
were used as controls for cell viability, and three wells con-
taining only complete medium were used as controls for
nonspecific dye reduction. After incubation, the plates were
centrifuged, the supernatants were removed, and 301l/well of
MTT solution with 10lIM of sodium succinate was added to
all the wells. The plates were incubated for an additional 4 h,
and 150 ll of dimethyl sulfoxide (DMSO) was then added to
all the wells (Carmichael et al., 1987); the mixtures were
pipetted thoroughly to dissolve the dark blue crystals. The
plates were then read on a microplate reader (Corona Elec-
tric, MTP-32) using a test wavelength of 570 nm and a
reference wavelength of 630 nm. The control wells without
tumour cells had an OD of less than 0.005, and the samples
in which the OD was over 0.1 were accepted for the assay.
The inhibition rate was calculated as follows:
Inhibition rate = (1 - OD drug treated/OD control) x 100
The background of tumour cells (including dead cells)
without addition of MTT had an OD of less than 0.012 after
96 h incubation, and the influence of dead tumour cells could
therefore be ignored in the present study. The viability of
tumour cells was maintained at 75-90% during the 96 h
incubation, and the OD570 values before and after 96 h
incubation were 0.36 ± 0.17, and 0.33 ± 0.14, respectively.
Chemotherapy on the basis ofthe results ofthe MTT assay
Twenty of the 51 patients whose tumour cells could be
assayed had evaluable lesions. These patients received cancer
chemotherapy on the basis of the results of the MTT assay.
Two or three drugs were administered, of which inhibition
rates were generally more than 50% at ten times the peak
plasma concentration. The disease stages in the remaining 31
patients were; four with Stage II; 12 with Stage IIIB, and 15
with Stage IV. The patients with Stage II and IIIB received
Tegafur (FT-207) orally as adjuvant chemotherapy following
curative operation. The patients with Stage IV were: ten with
T4N2MO and five with Ml (LYM), and they also received
cancer chemotherapy on the basis of the results of the MTT
assay. However, no evaluation could be done, since there
were no evaluable lesions after surgery.
Informed consent for the studies was obtained from all
subjects, in accordance with the guidelines of the Ethical
Committee on Human Research, Wakayama Medical Col-
lege.
Statisticalanalysis
Significant differences were determined by paired t-tests or
nonparametric Wilcoxon signed-rank test, and the general-
ised Wilcoxon test was used for survival. A P value of less
than 0.05 was considered to be statistically significant.
Results
Purity offresh human gastric cancer cells
The purity of tumour cells before and immediately after
enzymatic digestion alone for primary tumours and lymph nodes, or centrifugation alone for malignant ascites was
43.6±14.1%, 40.8±16.8% and 53.5±23.8% respectively. The purity after processing on the Ficoll-Hypaque discon-
tinous gradients increased to 63.9 ± 12.4%, 68.1 ± 13.2%
and 62.7 ± 17.1%, respectively. Tumour cells in solid
tumours, including primary and metastatic lymph nodes, and
in malignant ascites samples, were enriched to 90% using the
Percoll discontinuous gradients (P<0.01) (Table I).
Chemosensitivity ofpurifiedgastric tumour cells
At a drug concentration of Cmax x 10, the inhibition rates
of tumour cells for CDDP were higher than those for VP-16, 5-FU (P<0.01), and for DOX (P<0.05). However at
Cmax x 1, the inhibition rates for CDDP, MMC, DOX, and
5-FU were higher than that for VP-16 (Table II).
Comparison ofchemosensitivity between well andpoorly
differentiatedgastric cancer
Pathological examinations of primary gastric lesions showed
that 18 were the well differentiated (papillary and tubular
adenocarcinomas) and 15 were the poorly differentiated, in-
cluding six with signet-ring cell carcinoma and one with
mucinous adenocarcinoma.
As shown in Figure 1, there were no significant differences
between the chemosensitivity of the well differentiated and
the poorly differentiated type at drug concentrations of
Cmax x 10 and Cmax x 1. However, the inhibition rates
were slightly higher for the poorly differentiated tissues than
for the well differentiated tissues when exposed to MMC, DOX, and 5-FU at Cmax x 10, and DOX and 5-FU at
Cmax x 1 (0.05 <P<0.1) (Figure 1).
Clinical correlation
Of the 51 patients, 20 had evaluable lesions; and they received cancer chemotherapy according to the results of the
MTT assay using highly purified tumour cells. Clinical res-
Table I Purity of tumour cells
Purity (%) Preparation step Primary tumour Lymph nodes Ascites
n=33 n=8 n=8
(Absolute cell numbers: x 106)
Before purification 43.6± 14.1 40.8± 16.8 53.5±23.8
(31.5±9.9) (30.7± 11.1) (37.3± 14.8) After purification 92.2± 5+.3a 90.4±4.4a 91.8± 3.9a
(2.7± 0.8a) (2.6±0.9a) (2.8± 0.8a)
The tumour cells were enriched to a purity of90% afterpurification. ap<0.01, compared with thepurity or absolute cell numbers obtained
by enzymatic digestion or centrifugation alone. The absolute cell
numbersincluding tumour cells and nonmalignant cellsdecreased from 31.5 x 106 to 2.7 x 106 after purification in primary tumour.796 H. YAMAUE et al.
Table II Chemosensitivity ofpurified gastric cancer cells
Inhibition rates (%) by anticancer agents
Concentration CDDP VP-16 MMC DOX 5-FU
Cmax x 10 (n = 51) 66.1 ±28.4a 42.9±23.5b 63.1±26.3 54.9±30.2 49.0±26.2
Cmaxx I (n=32) 29.6±15.4c IL.6±11.7d 27.6±23.9 27.0±24.4 33.1±27.1
ap<0.01, compared with the inhibition rates of VP-16 and 5-FU; P<0.05, compared with
that ofDOX at Cmax x 10. bP<0.01, compared with that ofMMC; P<0.05, compared with
that of DOX. CP<0.01, compared with the inhibition rate of VP-16 at Cmax x 1. dP<O.Ol,
compared with that of MMC, DOX, and 5-FU. CDDP = cisplatin, VP-16 = etoposide,
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Figure 1 Comparison of chemosensitivity in well and poorly
differentiated gastric cancer. The chemosensitivity of gastric
cancer with poorly differentiated type was equivalent to that of
the well differentiated type not only at Cmax x 10, but also at
Cmax x 1.
ponses were obtained in 12 of the 20 patients (response rate:
60.0%). Ofthe five patients showing complete response (CR),
the lesions in two patients were metastatic lymph nodes,
including cervical lymph nodes and para-aortic lymph nodes.
Seven patients had a partial response (PR), of which the
evaluable lesions were three with malignant ascites, three
with metastatic lymph nodes, and one with abdominal
tumour (Table III).
Table IV shows the clinical outcomes of the nonresponders
to chemotherapy administered according to the MTT assay
results. Seven patients showed no change (NC); the lesions in
these patients were metastatic lymph nodes in four, and
malignant ascites in three. One patient with liver metastasis
had progressive disease (PD), and her survival was 2.6
months. The mean survival of responders (n = 12) was 264.4
days, and that of nonresponders (n
= 8) was only 134.6 days
(P = 0.013, by generalised Wilcoxon test). The mean survival
of five patients with Ml (LYM) among the 31 patients in
whom the lesions could not be evaluated was 192.0 days.
There was no difference in doses of anticancer drugs admin-
istered to patients who had a clinical response and those who
did not.
Comparison ofchemosensitivity in patients with and without
a clinical response
The inhibition rates for CDDP and MMC were significantly
.°° Um Isk{De" ANC; e+;f s,,;+ U ;>1 o"v txylkr 16-- nigiger tr U- u.u) in pa4LtCieLt Willl c1111141 repuonses Wnll na4U
received chemotherapy based on the results of the MTT
assay, than in those without clinical responses, whereas the
chemosensitivity for VP-16, DOX and 5-FU was equivalent
in the two groups (Table V).
Discussion
The MTT assay for chemosensitivity testing is a rapid and
semi-automated quantitative assay for screening the effects of
anticancer drugs on fresh tumour samples (Twentyman et al.,
1989; Wilson et al., 1990; Yamaue et al., 1991), as well as on
established cell lines (Twentyman et al., 1987; Carmichael et
al., 1987; Park et al., 1987). However, contamination by
non-malignant cells in tumour tissues influences the results of
this assay, although the nonmalignant cells are less sensitive
to anticancer drugs than the malignant cells (Maehara et al.,
1989; Yamaue et al., 1991; Kaspers et al., 1991). To use this
assay for leukaemic cells in peripheral blood or bone mar-
row, the cells must be enriched to more than 90% by centri-
fugation with 100% Ficoll-Hypaque alone (Sargent &
Taylor, 1989).
The MTT assay has been performed using malignant cells
from solid tumour samples, including lung cancer (Campling
et al., 1991) and ovarian cancer (Wilson et al., 1990) prepar-
ed with 100% Ficoll-Hypaque alone, or using malignant cells
from gastrointestinal cancer tissues prepared by enzymatic
digestion alone (Yamauchi et al., 1991). The purity ofmalig-
nant cells from ovarian cancer has been reported to be
relatively high; i.e. 70-80% (Wilson et al., 1990), however,
there is marked contamination by nonmalignant cells in gast-
ric cancer tissues as shown in the present study.
Thus, the MTT assay should be performed with highly
purified tumour cells in gastric cancer, since the chemosen-
sitivity of malignant tumour cells is distinct from that of
non-malignant cells, and moreover, since the chemosensitivity
of highly purified tumour cells is also distinct from that of
non-purified cells merely separated from tumour tissues
(Yamaue et al., 1991).
Gastrointestinal cancer is more resistant to anticancer
drugs than leukaemia and malignant lymphoma (Yamauchi
et al., 1991), and gastric adenocarcinoma is less sensitive to
these drugs than lung adenocarcinoma (Kohnoe et al., 1991).
In the present study, the inhibition rates of fresh human
gastric cancer cells with CDDP, MMC, DOX, and 5-FU
were 66.1%, 63.1%, 54.9%, and 49.0%, respectively, whereas
they were 57.9%, 49.3%, 40.6% and 26.4% in a study by
Kohnoe et al. (1991). The effective rates for CDDP, VP-16,
MMC, and DOX were 45.5%, 10.0%, 66.7% and 41.7%,
respectively (Ohyama et al., 1991) (all data at Cmax x 10).
The differences in these findings may be related to the
purification of the tumour cells. While Maehara et al. (1987)
found that the inhibition rates on the MTT assay were
remarkably high for poorly differentiated gastric cancer tis-
sues, exposed to CDDP, MMC, DOX, and 5-FU, compared
with those for well differentiated tissues. We found no signi-
ficant differences between the chemosensitivity of these two
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Table III Clinical response according to the MTT assay
Chemotherapy Survival
Case Age/Sex Stage Evaluable lesion (mean±s.d.a) Response (mo)
19 68/F IV Lymph nodes CDDP, VP-16 CR 9.7
(60±2) (47±2)
9 39/F IV Malignant ascites CDDP, VP-16 MMC CR 9.5
(68±3) (14±1) (55±2)
16 56/F IV Malignant ascites MMC, DOX, 5-FU CR 9.5
(88±3) (71±2) (76±3)
26 45/F IV Malignant ascites CDDP, VP-16 CR 10.9 (alive)
(66±3) (71±2)
46 28/F IV Lymph nodes CDDP CR 6.3 (alive)
(100±3)
21 62/M IV Abdominal tumour MMC, DOX, 5-FU PR 13.8
(89±3) (100±4) (56±2)
5 56/M IV Malignant ascites MMC, 5-FU PR 13.5
(98±4) (43±1)
2 39/F IV Malignant ascites CDDP, MMC PR 12.0
(99±3) (92±4)
11 66/F IV Malignant ascites CDDP, MMC PR 5.0
(100±3) (50±2)
29 52/M IV Lymph nodes CDDP, VP-16 PR 3.9
(84±5) (46±2)
25 59/F IV Lymph nodes CDDP, VP-16, DOX PR 3.5
(65±2) (72±4) (45±1)
40 51/M IV Lymph nodes CDDP, MMC PR 6.7 (alive)
(86±2) (51±3)
Cisplatin and mitomycin were administered intraperitoneally formalignantascites, and otherdrugs were
given intravenously. The absorbance values in OD570 of control wells with tumour cells alone were as
follows; Case 19 = 0.53, Case 9 = 0.17, Case 16 = 0.40, Case 26 = 0.25, Case 46 = 0.28, Case 21 = 0.39,
Case 5 = 0.33, Case 2 = 0.52, Case 11 = 0.75, Case 29 = 0.37, Case 25 = 0.37, and Case 40 = 0.29.
aMean±s.d. of the inhibition rates (%) in triplicate wells at Cmax x 10.
Table IV Nonresponders to chemotherapy given according to the MTT assay
Chemotherapy Survival
Case Age/Sex Stage Evaluable lesion (mean±s.d.a) Response (mo)
17 48/M IV Lymph nodes CDDP, DOX, 5-FU NC 9.8
(67±3) (36±1) (65±2)
35 63/M IV Lymph nodes MMC, DOX, 5-FU NC 7.4
(31±1) (48±2) (65±2)
13 65/F IV Malignant ascites CDDP, VP-16, MMC NC 4.7
(76±3) (58±2) (61±2)
3 51/F IV Malignant ascites CDDP, VP-16, MMC NC 3.5
(67±3) (31±1) (34±2)
7 58/M IV Lymph nodes CDDP, MMC, DOX NC 3.3
(72±3) (60±2) (61±2)
4 57/M IV Malignant ascites CDDP, VP-16, 5-FU NC 2.4
(55±4) (18±1) (50±2)
10 79/F IV Lymph nodes MMC, DOX, 5-FU NC 2.2
(60±3) (38±1) (47±2)
8 63/F IV Liver metastasis CDDP, VP-16, MMC PD 2.6
(45±1) (68±3) (64±2)
Theabsorbance values inOD570ofcontrol wells with tumourcellsalonewereas follows: Case 17 = 0.15,
Case 35 = 0.25, Case 13 = 0.36, Case 3 = 0.61, Case 7 = 0.35, Case4 = 0.43, Case 10 = 0.34, Case 8 = 0.28.
aMean±s.d. of the inhibition rates (%) in triplicate wells at Cmax x 10.
Another problem associated with the clinical application of
the MTT assay is the determination of optimal conditions for
the evaluation of chemosensitivity and drug concentration.
Camling et al. (1991) and Schroyens et al. (1990) reported
that the data for the MTT assay in established cell lines
should be expressed as the area under the dose response
curves (AUC); however, the usefulness of the MTT assay in
clinical samples may be of limited value, since adequate
numbers of tumour cells, to enable the assessment of the
AUC for several drugs, cannot always be obtained in all
cases. Therefore, we used two drug concentrations, including
Cmax x 10 and Cmax x 1, for the MTT assay of clinical
samples; however, Cmax levels of drugs will vary according
to the method of measurement, the clinical protocol, and the
individual patient. Many other factors are also involved in
drug activity, including alterations to drug metabolites.
In chemosensitive leukaemia, since the lethal concentration
to 50% of the cells (LDm) in the dose-response curve was
found to be equivalent to Cmax x 1, drugs induced 50%
cytotoxicity were considered to be effective at Cmax x 1
(Kaspers et al., 1991). In an MTT assay for ovarian cancer,
Wilson et al. (1990) employed the criteria used for predicting
in vivo sensitivity in haematological malignancy, in which the
drug concentration was equivalent to Cmax x 2 (Weisenthal
et al., 1986). On the other hand, in human colo-rectal car-
cinoma cell lines, the AUC which produced 50% growth
inhibition was within a clinically achievable range (Cmax x 1)
only for 5-FU (Park et al., 1987), and Cmax x 10-100 was
required to reduce 50% of the AUC for other drugs, includ-
ing CDDP, VP-16, MMC and DOX. These findings are
supported by our results that the inhibition rates of 5-FU
were 49.0% at Cmax x 10, and 33.1% at Cmax x 1, and that
the difference between Cmax x 10 and Cmax x 1 was mini-
mal. In fresh human gastrointestinal cancer, the concentra-798 H. YAMAUE et al.
Table V Comparison ofchemosensitivity in patients with and without clinical response
Inhibition rates (%) by anticancer agents
CDDP VP-16 MMC DOX S-FU
Response (+) (n = 12) 80.9±15.5a 49.9±21.1 74.7±19.9a 72.1± 22.5 57.3± 14.0
Response (-) (n = 8) 63.5± 10.7 43.9±20.0 51.6±12.5 45.7±9.97 54.1± 7.85
ap<0.05, compared to nonresponders.
tion of drugs used in the MTT assay has usually been
Cmax x 10 (Maehara et al., 1987; Yamaue et al., 1991;
Ohyama et al., 1991). In the present study, the inhibition
rates obtained with anticancer drugs ranged from 11.6%
(VP-16) to 33.1% (5-FU) at Cmax x 1, and the evaluation
could be performed. Therefore, the results obtained at
Cmax x 1 should be considered to be clinically applicable.
In retrospective studies, the MTT assay has accurately
predicted the initial response to chemotherapy in acute
leukaemia (Sargent & Taylor, 1989; Santini et al., 1989), as
well as the long-term clinical outcome (Pieters et al., 1991).
The present study was prospective, being designed to deter-
mine chemotherapy according to the results of the MTT
assay. Clinical response rate was obtained in 12 of the 20
patients (60.0%). We consider this rate to be relatively high,
since the response rate for conventional chemotherapy in
gastric cancer in our hospital was only 15.9% (Yamaue et al.,
1990c). However, a prospective randomised-controlled study
with an adequate number of patients is required for the
evaluation of whether the results of the MTT assay in vitro
correlate with the clinical response in vivo.
Our investigations continue, by a randomised-controlled
prospective study with adequate number of patients, to
examine whether the results of the MTT assay using highly
purified fresh human tumour cells correlate with clinical res-
ponse, and further, which drug concentrations should be
used in the MTT assay.
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